NASDAQ Biotech Index Up 2.56%, Medicure Will Be $30+ Within 12 Months

The NASDAQ Biotechnology Index (IBB) is up by 2.56% today and NIA’s President is continuing to add to his Medicure (TSXV: MPH) position. MPH is the world’s #1 most undervalued biotech stock and will be $30+ per share within the next 12 months.

The U.S. Food and Drug Administration has granted both Rare Pediatric Disease Designation and Orphan Drug Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. In addition, the European Medicines Agency has granted Orphan Drug Designation to MC-1 for the treatment of PNPO deficiency. Medicure has also received Fast Track Designation for MC-1 in PNPO deficiency, which is intended to facilitate the development and review of a future New Drug Application by the FDA.

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.